PHARMA-BIO SERV, INC. (PBSV)

Every figure this model derived for PBSV, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2026-04-30.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 7,118 PaymentsToAcquirePropertyPlantAndEquipment 2026-04-30
cash 8,472,308 CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents 2026-04-30
current assets 11,286,272 AssetsCurrent 2026-04-30
current liabilities 1,045,169 LiabilitiesCurrent 2026-04-30
equity 10,454,229 StockholdersEquity 2026-04-30
interest expense 0 InterestPaidNet 2025-10-31
ocf -239,260 NetCashProvidedByUsedInOperatingActivities 2026-04-30
revenue 9,110,628 Revenues 2026-04-30
sbc 31,636 ShareBasedCompensation 2026-04-30

The ratios

The figures themselves rather than their scores — what somebody looking up PBSV on one particular measure came for.

RatioValue
cash operating margin-3.35
current ratio10.8
current ratio reported10.8
dilution pct-0.08
fcf margin-2.7
operating margin-4.36
owner earnings margin-3.05
revenue growth-5.49
revenue growth per share-5.42
roic-15.82
rule of 40-9.85
sbc pct revenue0.35

What to be careful about

What this model itself distrusts about PBSV's figures. Written by the derivation as it ran, not added afterwards.